Dyax Announces Positive Final Results from Phase I Trial of Subcutaneous DX-88

Positive Experience with Subcutaneously Administered DX-88 in the Ongoing, Phase II Open-Label EDEMA2 Trial for Hereditary Angioedema

09-Nov-2005

Dyax Corp. announced positive final data from its completed Phase I trial, demonstrating that DX-88 was safe and well tolerated in normal volunteers when administered subcutaneously. Dr. Thomas R. Beck, Executive Vice President, Business and Product Development of Dyax, also reported positive initial experience in 31 attacks treated subcutaneously with DX-88 in the ongoing, Phase II open-label EDEMA2 study. DX-88 is being developed in a joint venture with Genzyme Corporation for the treatment of hereditary angioedema (HAE), a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of severe peripheral, abdominal and/or laryngeal pain and swelling.

Based on the pharmacokinetic and safety profiles observed in the Phase I trial, Dyax has now converted all clinical sites in the ongoing EDEMA2 trial from intravenous (IV) dosing to the more easily administered subcutaneous (SQ) injection of DX-88. This conversion has provided HAE patient experience with SQ DX-88 prior to the initiation of a pivotal Phase III trial planned to start before year end. Recently, Dyax has sent the Phase III protocol to 47 U.S. and Canadian sites. Dyax expects the IRB approval process to go smoothly and already has sites with identified patients, awaiting enrollment. Dyax, together with Genzyme, remains committed to bringing DX-88 to the marketplace as the first subcutaneously administered treatment for the HAE patient community.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances